Company Information
CIN
Status
Date of Incorporation
07 September 1973
State / ROC
Bangalore / ROC Bangalore
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2023
Paid Up Capital
243,604,492
Authorised Capital
340,000,000
Directors
Grama Seshamurthy Balaji
Director/Designated Partner
over 2 years ago
over 2 years ago
Badarinath Krishtachary Ibrampur
Director/Designated Partner
over 2 years ago
over 2 years ago
Dilip Surana
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Anand Surana
Director/Designated Partner
over 3 years ago
over 3 years ago
Vijay Kantilal Shah
Director/Designated Partner
over 11 years ago
over 11 years ago
Pinky Jain
Director/Designated Partner
over 11 years ago
over 11 years ago
Monica Surana
Director
about 17 years ago
about 17 years ago
Past Directors
Amar Singh Sisodia
Whole Time Director
over 14 years ago
over 14 years ago
Subbarao Prasanna
Director
over 18 years ago
over 18 years ago
Patents
The present invention relates to use of fixed dose combination comprising Ketorolac or its pharmaceutically acceptable salts thereof and Difluprednate for the treatment of post operative ocular inflammation. The present invention further relates to a pharmaceutical composition comprising fixed dose combination compr...
An extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same. The present invention particularly relates to an extended release pharmaceutical composition comprising Paliperidone or pha...
The present invention relates to a novel stable immediate release pharmaceutical composition comprising Cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and the process for preparing the same, whereas the composition of the present invention has in-vitro dissolution p...
The present invention relates to oral pharmaceutical compositions comprising active Choline Fenofibrate optionally with one or more pharmaceutically acceptable excipient(s), wherein the said active agent is not essentially present in core composition and is devoid of molecular dispersion. The present invention also ...
A process of sterilization of ophthalmic suspension comprising brinzolamide using ethylene oxide.
The present invention relates to an improved process for the preparation of Darunavir or solvates or a pharmaceutically acceptable salt thereof.
There is provided a pharmaceutical composition comprising Irbesartan.
There is provided a process for preparing sustained release pharmaceutical composition comprising Sodium Valproate and valproic acid.
Novel Process for Preparation of Physicochemically Stable Oral Suspension
Abstract of the Invention
The present invention describes process of preparation of physicochemically stable oral suspension formulation containing mebeverine or pharmaceutically acceptable salts thereof, optionally with one or more phar...
The present invention relates to stable oral pharmaceutical compositions comprising Rasagiline or a pharmaceutically acceptable salt thereof with at least one or more pharmaceutically acceptable antioxidant(s), wherein the said composition is free of sugar alcohols. The present invention also describes process for t...
The present invention relates to a pharmaceutical composition comprising Roflumilast. Particularly, the present invention
provides a pharmaceutical composition in the form of a tablet or a capsule comprising Roflumilast and pharmaceutically ac -
ceptable excipients and a process for preparing the same.
...
ABSTRACT
The present invention relates to sustained release oral stable pharmaceutical compositions comprising active Lacosamide, optionally with one or more pharmaceutically acceptable excipient(s), wherein the said composition is devoid of any rate controlling polymer. The present invention also provides proces...
The present invention relates to an extended release pharmaceutical composition comprising diltiazem. Particularly, the present invention provides an extended release pharmaceutical composition in the form of a tablet or a capsule comprising diltiazem, release controlling agent(s) and a process for preparing the sam...
The present invention relates to a cost effective, novel and efficient process for the preparation of Brivaracetam which offers industrially viable, highly pure Brivaracetam in high yields and avoiding chiral resolutions by chromatography and enzymatic resolutions.
The present invention relates to a process for preparing a pharmaceutical composition comprising Rivaroxaban in the form of a tablet or a capsule.
A non-osmotic coated extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same. The present invention particularly relates to a non-osmotic coated extended release pharmaceutical compos...
An extended release pharmaceutical composition comprising amoxicillin and clavulanic acid or pharmaceutical^ acceptable salts thereof and a process for preparing thereof. The present invention particularly relates to composition containing various coatings in order to retard the release of the drug from tablet.
...
The present invention relates to use of a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections. The pr...
The present invention provides pharmaceutical composition comprising pregabaUn that is useful for once daily oral dosing. The present invention further relates to pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing comprising pregabalin and on or more water insoluble components...
The present invention relates to a novel process for preparing ebastine from 1-[4-(1,1-dimethylethyl) phenyl]-4-(4-hydroxy piperidin-1-yl) butan-1-one and dipheriyl methanol, which is easily reproducible on an industrial scale. A process for preparation of 1-[4-(1,1-dimethylethyl) phenyl]-4-(4-hydroxy piperidin-1-yl...
The present invention relates to a pharmaceutical combination comprising a prostaglandin compound and a NSAID. The present invention particularly relates to an ophthalmic composition comprising travoprost and bromfenac for the treatment of glaucoma and ocular hypertension.
The present invention is related a stable painless parenteral solution comprising 75 mg /ml of diclofenac or a pharmaceutically acceptable diclofenac salt. More specifically, the present invention is related a stable painless parenteral solution comprising 75 mg /ml of diclofenac or a pharmaceutically acceptable dic...
A prostaglandin composition comprising prostaglandin and a low-density polyethylene container are disclosed. The prostaglandin compositions are stable in polyethylene containers over longer period of time.
Disclosed herein is an improved process for the preperation of (4S, 6S)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide (Dorzolamide) and its intermediates.
present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hy...
There are provided lactose based coatings for pharmaceutical compositions. The present invention relates to lactose based coating for pharmaceutical compositions, which is resistant to discoloration of pharmaceutical compositions.
There is provided a modified release solid pharmaceutical composition comprising
Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.
The present invention relates to use of a fixed dose combination comprising Azelastine or its pharmaceutically acceptable salts thereof and Cromolyn or its pharmaceutically acceptable salts thereof for the treatment of ocular allergy. The present invention further relates to a pharmaceutical composition comprising f...
The present invention relates to extended release pharmaceutical composition such as tablets and capsules, and in particular to a matrix tablet composition for oral administration comprising a therapeutically effective quantity of Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite ther...
The present invention provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid or pharmaceutically acceptable salt, derivative, prodrug, metabolite and polymorph thereof and one or more pharmaceutically acceptable excipients and a process of preparing the same. The ...
“AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES THEIR ISOMERS AND SALTS THEREOF”
Abstract of the Invention
The present invention relates to an improved and one-pot process for the preparation of 1-Aryl 2-aminomethyl cyclopropane carboxyamide (z) derivat...
AN IMPROVED PROCESS FOR THE PREPARATION OF PURE CYAMEMAZINE AND SALTS THEREOF
Abstract of the Invention
The present invention provides an improved process for the preparation of cyamemazine of formula-1 or its pharmaceutically acceptable salt thereof, which is substantially free of impurities.
...
There is provided a stabilized pharmaceutical composition comprising Gabapentin with minimum levels of pharmaceutically acceptable inert excipients.
The present invention is related to ophthalmic composition comprising Timolol, Dorzolamide and Brimonidine. More specifically, the present invention is related to a stable ophthalmic composition comprising Timolol, Dorzolamide and Brimonidine and hydroxyethyl cellulose.
An extended release matrix tablet for once daily administration comprising Carbamazepine or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same and is bioequivalent to FDA approved Carbamazepine extended release tablet formulations (TEGRETOL ® -XR).
...
The present invention is directed to a pharmaceutical composition comprising a pharmacologically effective amount of Travoprost, a pharmacologically effective amount of Timolol Maleate, and a pharmacologically effective amount of Brimonidine Tartrate for the treatment of glaucoma and ocular hypertension. The present...
The present invention relates to a novel, industrially feasible process for preparation of Isoprenaline hydrochloride via novel intermediates.
The present invention relates to orally disintegrating tablets comprising Metopimazine and process for its preparation. More specifically, the present invention relates to an orally disintegrating tablets comprising taste masked granules of Metopimazine and one or more pharmaceutically acceptable excipients, wherein...
The present invention relates to an optimized process for preparing storage stable amorphous Ivabradine hydrochloride in high yield.
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF AN ORAL ANTICOAGULANT COMPOUND
The present invention relates to an improved process for preparing Edoxaban (I) or its pharmaceutically acceptable salts or solvates thereof.
MIRABEGRON COMPLEX
Abstract Of The Invention
The present invention relates to novel complex of Mirabegron with cyclic oligosaccharides. The said complex is prepared by dissolving Mirabegron and cyclic oligosaccharides in suitable solvents and then removing solvent by suitable techniques. Further the present i...
Stable Dapagliflozin and its Pharmaceutical Composition
The present invention relates to a process for preparation of stable Dapagliflozin or its pharmaceutical salts thereof. The present invention also relates to method of treating diabetes using a pharmaceutical composition comprising stable form of Dapaglifl...
Abstract of the Invention
The present invention relates to a liquid oral pharmaceutical composition comprising;
a) Solution of Cyclizine or a pharmaceutically acceptable salts thereof with cyclodextrin and one or more pharmaceutically acceptable excipients.
b) Suspension of Cyclizine or a pharmaceutically accept...
The present invention relates to an improved process for the preparation of Bilastine using novel intermediates of Formula III and IV
The present invention relates to an extended release pharmaceutical composition of Oxcarbazepine, wherein said composition does not contain pH-dependent soluble polymer. Particularly, the present invention relates to an extended release pharmaceutical composition of Oxcarbazepine comprising hydrophilic polymer and/o...
The present invention provides an improved process for the preparation of Rilpivirine and its pharmaceutically acceptable salts by using novel intermediate compound of formula (IV). The present invention further provides a process for the preparation of Rilpivirine hydrochloride Form A.
The present invention relates to an extended release pharmaceutical composition comprising topiramate and its pharmaceutically acceptable excipients, wherein topiramate is present in three different portions in varied percentages.
The present invention relates to modified release formulation of Pregabalin and process for its preparation wherein said formulation does not contain hydrophobic release controlling polymer. The present invention also relates to modified release pharmaceutical composition comprising Pregabalin, conventional release ...
The present invention relates to a novel stable, sustained release composition of Clindamycin or its pharmaceutical acceptable salts, wherein the said composition is prepared by the matrix technology using water soluble release controlling polymers.
The present invention relates to a cost effective and efficient process for the preparation of Brivaracetam which offers industrially viable, highly pure Brivaracetam in high yields.
The present invention relates to a process for the preparation of (S)-Netarsudil or its pharmaceutically acceptable salts using novel intermediates. The present invention further provides novel salts, novel intermediates and novel polymorphic forms of the (S)-Netarsudil salts and process for the preparation of the s...
The present invention relates to an improved process for the preparation of Bempedoic acid of Formula I using a novel intermediate of Formula VIII, wherein R1 is optionally substituted C1-C6 alkyl, aryl or arylalkyl.
The present invention is directed to combination composition of Simethicone and Phloroglucinol Dihydrate. More specifically, the present invention relates to capsule comprising pellets of Simethicone and pellets of Phloroglucinol and one or more pharmaceutically acceptable excipients, wherein the pellets are prepare...
The present invention provides an ophthalmic composition of Brimonidine, Timolol and Brinzolamide or their pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. More particularly, the present provides an ophthalmic composition of Brimonidine Tartrate, Timolol Maleate and B...
The present invention relates to an improved process for preparation of Mavacamten, in particular crystalline form A of Mavacamten. Mavacamten obtained by the process of the present invention is highly pure and obtained in high yield without the need of multiple purification steps.
The present invention relates to an ophthalmic composition of Brinzolamide. More particularly, the present invention relates to an ophthalmic solution of Brinzolamide comprising Brinzolamide dispersed uniformly in a polymer in form of polymeric micelles. Further, the present invention relates to aqueous micelle solu...
Present invention relates to an improved process for the preparation of Deucravacitinib and intermediates thereof. The process of the present invention is simple, involves economically and easily available starting materials and is up-scalable to the industrial level.
Registered Trademarks
[Class : 5] Pharmaceutical, Medicinal Preparations For Purposes Including Pain Management, Veterinary And Sanitary Preparations; Dietetic Substances Adapted For Medical Use, Food For Babies; Plasters And Materials For Dressings.
[Class : 5] Pharmaceutical, Medicinal Preparations For Purposes Including Pain Management; Ayurvedic And Herbal Preparations Including Medicated Oil For Pain Management; Dietetic Substances Adapted For Medical Use; Veterinary And Sanitary Preparations; Food For Babies; Plasters And Materials For Dressings.
[Class : 5] Pharmaceutical, Medicinal Preparations For Purposes Including Pain Management, Veterinary And Sanitary Preparations; Dietetic Substances Adapted For Medical Use, Food For Babies; Plasters And Materials For Dressings.
View +1364 more Brands for Micro Labs Limited.
Charges
30 January 2018
Indusind Bank Ltd.
38 Crore
21 April 2017
The Hongkong And Shanghai Banking Corporation Limited
379 Crore
20 February 2017
State Bank Of India
135 Crore
24 January 2014
The Hongkong And Shanghai Banking Corporation Limited
389 Crore
29 June 2013
The Hongkong And Shanghai Banking Corporation Limited
120 Crore
04 July 2012
Citi Bank N.a.
40 Crore
28 December 2011
The Hongkong And Shanghai Banking Corporation Limited
15 Crore
28 June 2011
Dbs Bank Limited
100 Crore
31 July 2008
Citibank N.a.
40 Crore
29 September 2006
Abn Amro Bank Nv
55 Crore
26 June 2006
Standard Chartered Bank
150 Crore
30 March 2002
Canara Bank
20 Crore
28 January 2000
Canara Bank
11 Crore
04 January 1999
Canara Bank
6 Crore
29 June 1998
State Bank Of Mysore
1 Crore
29 June 1998
State Bank Of Mysore
50 Lak
29 October 1997
State Bank Of Mysore
6 Crore
03 March 1997
Canara Bank
50 Lak
09 May 1996
Canara Bank
5 Crore
04 February 1995
Canara Bank
250 Crore
30 August 1994
Canara Bank
64 Lak
25 May 1994
Canara Bank
79 Lak
09 April 1994
State Bank Of Mysore
2 Crore
24 January 1994
Central Bank Of India
15 Lak
14 July 1993
Central Bank Of India
10 Lak
05 March 1993
Canara Bank
25 Lak
15 September 1992
Canara Bank
2 Crore
03 June 1992
Canara Bank
25 Lak
09 December 1991
Canara Bank
15 Lak
25 January 1990
Canara Bank
1 Crore
25 January 1990
Canara Bank
1 Crore
24 January 1990
Canara Bank
2 Crore
20 December 1987
Canara Bank
70 Lak
20 December 1987
Canara Bank
40 Lak
26 August 1986
Canara Bank
30 Lak
10 April 1985
Canara Bank
10 Lak
04 February 1985
Canara Bank
5 Crore
29 December 1983
Canara Bank
3 Lak
19 August 1983
Canara Bank
5 Lak
10 August 1982
Canara Bank
5 Lak
29 December 1981
Canara Bank
10 Lak
25 September 1981
Canara Bank
10 Lak
23 September 1981
Canara Bank
13 Lak
23 September 1981
Canara Bank
13 Lak
13 March 1980
Central Bank Of India
55 Lak
11 September 1979
Canara Bank
2 Lak
04 September 1979
Canara Bank
45 Thousand
17 December 1978
Canara Bank
2 Lak
30 August 1976
Canara Bank
6 Lak
30 August 1976
Canara Bank
6 Lak
21 August 1976
Canara Bank
3 Lak
21 August 1976
Canara Bank
3 Lak
20 February 2017
State Bank Of India
22 Crore
09 June 2007
Standard Chartered Bank
55 Crore
21 April 2011
Barclays Bank Plc
30 Crore
31 January 2005
Idbi Bank Limited
30 Crore
23 November 2012
Hsbc Bank (mauritius) Limited
110 Crore
17 December 2007
Standard Chartered Bank
137 Crore
09 December 2010
Standard Chartered Bank
92 Crore
14 January 2011
Standard Chartered Bank
92 Crore
27 August 2003
State Bank Of India
13 Crore
22 October 2007
The Royal Bank Of Scotland N. V.
35 Crore
05 November 2008
Barclays Bank Plc
30 Crore
31 January 2005
Idbi Bank Limited
15 Crore
27 September 2005
Export- Import Bank Of India
22 Crore
26 March 2004
Export-import Bank Of India
17 Crore
26 March 2004
Export-import Bank Of India
5 Crore
15 June 2020
Axis Bank Limited
52 Crore
18 June 2022
City Union Bank Limited
0
20 February 2017
State Bank Of India
0
30 January 2018
Others
0
15 June 2020
Axis Bank Limited
0
28 December 2011
The Hongkong And Shanghai Banking Corporation Limited
0
23 September 1981
Canara Bank
0
24 January 1990
Canara Bank
0
25 January 1990
Canara Bank
0
15 September 1992
Canara Bank
0
28 January 2000
Canara Bank
0
21 August 1976
Canara Bank
0
30 August 1976
Canara Bank
0
04 September 1979
Canara Bank
0
11 September 1979
Canara Bank
0
23 September 1981
Canara Bank
0
25 September 1981
Canara Bank
0
29 December 1981
Canara Bank
0
29 December 1983
Canara Bank
0
26 August 1986
Canara Bank
0
20 December 1987
Canara Bank
0
25 January 1990
Canara Bank
0
09 December 1991
Canara Bank
0
03 June 1992
Canara Bank
0
05 March 1993
Canara Bank
0
25 May 1994
Canara Bank
0
30 August 1994
Canara Bank
0
09 May 1996
Canara Bank
0
03 March 1997
Canara Bank
0
04 January 1999
Canara Bank
0
30 March 2002
Canara Bank
0
21 August 1976
Canara Bank
0
30 August 1976
Canara Bank
0
17 December 1978
Canara Bank
0
10 August 1982
Canara Bank
0
19 August 1983
Canara Bank
0
04 February 1985
Canara Bank
0
10 April 1985
Canara Bank
0
20 December 1987
Canara Bank
0
09 June 2007
Standard Chartered Bank
0
26 June 2006
Standard Chartered Bank
0
29 September 2006
Abn Amro Bank Nv
0
20 February 2017
State Bank Of India
0
14 July 1993
Central Bank Of India
0
13 March 1980
Central Bank Of India
0
21 April 2011
Barclays Bank Plc
0
09 December 2010
Standard Chartered Bank
0
14 January 2011
Standard Chartered Bank
0
21 April 2017
Others
0
17 December 2007
Standard Chartered Bank
0
04 February 1995
Canara Bank
0
24 January 1994
Central Bank Of India
0
29 June 1998
State Bank Of Mysore
0
04 July 2012
Citi Bank N.a.
0
09 April 1994
State Bank Of Mysore
0
29 October 1997
State Bank Of Mysore
0
29 June 1998
State Bank Of Mysore
0
27 August 2003
State Bank Of India
0
31 January 2005
Idbi Bank Limited
0
26 March 2004
Export-import Bank Of India
0
27 September 2005
Export- Import Bank Of India
0
26 March 2004
Export-import Bank Of India
0
31 January 2005
Idbi Bank Limited
0
24 January 2014
Others
0
23 November 2012
Hsbc Bank (mauritius) Limited
0
28 June 2011
Dbs Bank Limited
0
05 November 2008
Barclays Bank Plc
0
31 July 2008
Citibank N.a.
0
22 October 2007
The Royal Bank Of Scotland N. V.
0
29 June 2013
The Hongkong And Shanghai Banking Corporation Limited
0
18 June 2022
City Union Bank Limited
0
20 February 2017
State Bank Of India
0
30 January 2018
Others
0
15 June 2020
Axis Bank Limited
0
28 December 2011
The Hongkong And Shanghai Banking Corporation Limited
0
23 September 1981
Canara Bank
0
24 January 1990
Canara Bank
0
25 January 1990
Canara Bank
0
15 September 1992
Canara Bank
0
28 January 2000
Canara Bank
0
21 August 1976
Canara Bank
0
30 August 1976
Canara Bank
0
04 September 1979
Canara Bank
0
11 September 1979
Canara Bank
0
23 September 1981
Canara Bank
0
25 September 1981
Canara Bank
0
29 December 1981
Canara Bank
0
29 December 1983
Canara Bank
0
26 August 1986
Canara Bank
0
20 December 1987
Canara Bank
0
25 January 1990
Canara Bank
0
09 December 1991
Canara Bank
0
03 June 1992
Canara Bank
0
05 March 1993
Canara Bank
0
25 May 1994
Canara Bank
0
30 August 1994
Canara Bank
0
09 May 1996
Canara Bank
0
03 March 1997
Canara Bank
0
04 January 1999
Canara Bank
0
30 March 2002
Canara Bank
0
21 August 1976
Canara Bank
0
30 August 1976
Canara Bank
0
17 December 1978
Canara Bank
0
10 August 1982
Canara Bank
0
19 August 1983
Canara Bank
0
04 February 1985
Canara Bank
0
10 April 1985
Canara Bank
0
20 December 1987
Canara Bank
0
09 June 2007
Standard Chartered Bank
0
26 June 2006
Standard Chartered Bank
0
29 September 2006
Abn Amro Bank Nv
0
20 February 2017
State Bank Of India
0
14 July 1993
Central Bank Of India
0
13 March 1980
Central Bank Of India
0
21 April 2011
Barclays Bank Plc
0
09 December 2010
Standard Chartered Bank
0
14 January 2011
Standard Chartered Bank
0
21 April 2017
Others
0
17 December 2007
Standard Chartered Bank
0
04 February 1995
Canara Bank
0
24 January 1994
Central Bank Of India
0
29 June 1998
State Bank Of Mysore
0
04 July 2012
Citi Bank N.a.
0
09 April 1994
State Bank Of Mysore
0
29 October 1997
State Bank Of Mysore
0
29 June 1998
State Bank Of Mysore
0
27 August 2003
State Bank Of India
0
31 January 2005
Idbi Bank Limited
0
26 March 2004
Export-import Bank Of India
0
27 September 2005
Export- Import Bank Of India
0
26 March 2004
Export-import Bank Of India
0
31 January 2005
Idbi Bank Limited
0
24 January 2014
Others
0
23 November 2012
Hsbc Bank (mauritius) Limited
0
28 June 2011
Dbs Bank Limited
0
05 November 2008
Barclays Bank Plc
0
31 July 2008
Citibank N.a.
0
22 October 2007
The Royal Bank Of Scotland N. V.
0
29 June 2013
The Hongkong And Shanghai Banking Corporation Limited
0
Documents
Form MGT-14-13022021_signed
Form DPT-3-06112020-signed
Form MGT-14-03112020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-03112020
Optional Attachment-(1)-03112020
Form MSME FORM I-31102020_signed
Form MGT-14-30092020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-28092020
Optional Attachment-(1)-28092020
Optional Attachment-(2)-28092020
Form PAS-6-11092020_signed
Optional Attachment-(1)-11092020
Form PAS-6-31082020_signed
Optional Attachment-(1)-31082020
Form INC-28-30072020-signed
Optional Attachment-(1)-28072020
Copy of court order or NCLT or CLB or order by any other competent authority.-28072020
Form MGT-14-10072020_signed
Optional Attachment-(4)-10072020
Optional Attachment-(1)-10072020
Optional Attachment-(3)-10072020
Optional Attachment-(2)-10072020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-10072020
Optional Attachment-(5)-10072020
Optional Attachment-(1)-10072020
Instrument(s) of creation or modification of charge;-10072020
Form CHG-1-10072020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200710
Copy of court order or NCLT or CLB or order by any other competent authority.-08072020
Form INC-28-18062020-signed
